Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06346405
Recruiting Observational

Central Serous Chorioretinopathy and Micropulse Laser Treatment

NCT06346405 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2023-05-31
Last updated
2025-09-23

Condition(s) studied

Central Serous Chorioretinopathy

Investigational drug(s) / intervention(s)

Subthreshold Micropulse Laser Treatment

Subthreshold Micropulse Laser Treatment: Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.

Study summary

To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months. * Foveal serous retinal detachment for at least 6 months. * Minimum age of 18 years old at the screening time * Reading and comprehension skills of informed consent Exclusion Criteria: * Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone * No diffuse retinal epitheliopathy * Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization * Not controlled glaucoma with eyedrops, or advanced glaucoma * Myopia or hypermetropia greater than 6 diopters * Opacities of dioptric media * Low quality of optical coherence tomography (OCT) and OCT-Angiography scans * Low quality images of Fluorescein angiography and indocyanine green angiography * No written consensus signed.

Primary outcome measure(s)

  • Vessel density changes — 12 and 24 months
    Evaluation of changes in vessel density of choriocapillaris by optical coherence tomography (OCT) angiography before and after treatment

Trial sites (1)

FacilityCityRegionStatus
Fondazione Policlinico Agostino Gemelli, IRCCS Roma R Recruiting

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

The Management of Asymptomatic Carotid Stenosis Recruiting
Modular Neurological Examination for Early Risk Detection Active, not recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. Recruiting
BRCA Mutation Carriers' Platform a Multicenter Study Recruiting
Superior Cervical Ganglion in Parkinson's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06346405 on ClinicalTrials.gov ↗ ← All trials in Italy